A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.
← catalyst calendarSponsored by Bausch & Lomb Incorporated (industry) · BLCO — their whole pipeline →.
Phase
Phase 4
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Single · Treatment
Enrollment
216actual
Sites
12
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-07-31 | actual | When the study began enrolling |
| Primary completion | Nov 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Nov 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2024-12-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dry Eye
Interventions
- Drug: Miebo
- Drug: Saline
Primary outcome
what the primary-completion date above is the date OFMean change from baseline in ECD
measured Assessed at Month 3 and Month 12 Visits
Permalink · BLCO's whole pipeline · Catalyst calendar · Every registered study · What changed